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ABSTRACT
Malaria is a fatal yet preventable and treatable disease. It is commonly spread through the
bite of an infected Anopheles mosquito. Malaria parasites belong to the Plasmodium genus and
can be caused by the falciparum, malariae, ovale, vivax, and knowlesi species. Artemisinin is an
endoperoxide lactone extracted from qinghaosu (Artemisia annua L. or sweet wormwood). It and
its derivatives possess uncharacteristically rapid action against Plasmodium falciparum.
Artemisinin is unique in its effectiveness in deadly cerebral malaria. The endoperoxide bridge is
crucial for its antimalarial activity; however, how it aids in killing the parasite is unknown.
While there are multiple suggested modes of action (MOA) for artemisinin, none to date
have a well-characterized protein target except for PfATP6, proposed by Krishna, et al. His
work suggested that artemisinin binds to the homologous thapsigargin binding site of PfATP6.
Herein, knowledge of the previously proposed mechanisms was utilized along with numerous
computational techniques to determine a more detailed and plausible MOA for artemisinin
against PfATP6. This led to the discovery of two new, putative PfATP6 binding sites for
artemisinin.
None of the previous work has explained the co-dependence of antimalarial efficacy on
the concentration of Fe(II). In our work, we searched for putative sites containing a cysteine
residue, Fe(II) and artemisinin in a conformation allowing for the well-accepted ring-opened C4
primary artemisinin carbon radical to form a covalent bond with a cysteine thiol rather than
undergoing an intramolecular self-emolative diradical ring closure. Clearly there are geometric
ii

constraints for a transition state that side-steps the latter reaction and instead allows for
interception by a cysteine thiol. We have suggested mechanistic possibilities for this capture by
the artemisinin C4 radical and propose that PfATP6 is deactivated by blocking the Ca(II) channel
by the modification of a cysteine at either C1031 or C92. It is alternatively possible that these
modifications lead to alterations in the function of the protein, rendering it dysfunctional.
Structure-based virtual screening was then used to screen a commercial database of
compounds to find novel inhibitors of PfATP6. Biological testing will be done to determine if
targeting these new sites can produce potent antimalarials with less structural complexity than
artemisinin itself.
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CHAPTER 1
INTRODUCTION
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1.1

MALARIA
Malaria is one of the world’s most fatal diseases, although it is preventable and treatable.1 It

is the world’s third most deadly infectious disease, falling behind tuberculosis and pneumococcal
respiratory infections. It is a mosquito-borne infectious disease that affects humans and other
animals. The disease is commonly spread through the bite of an infected Anopheles mosquito.2
As of 2013, 97 countries had ongoing malaria transmission. According to the World Health
Organization (WHO), 3.4 billion people are at risk of malaria with 1.2 billion people being at
high risk. In 2012 there was an estimated 207 million cases and an estimated 627,000 deaths
from malaria with approximately 90 percent of the deaths occurring in sub-Saharan Africa. In the
same year, malaria killed around 482,000 children under five years of age. This adds up to 1,300
children per day or one child almost every minute.3

Malaria parasites belong to the Plasmodium genus. Human malaria is caused by the
Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax, and
Plasmodium knowlesi species.5 Infection by all species of Plasmodium begins with the bite of an
infected female Anopheles mosquito. After a silent infectious phase in the liver hepatocytes,
exoerythrocytic merozoites pass into the bloodstream as merosomes that eventually rupture. This
allows the parasite access to circulating erythrocytes. Merozoites rapidly invade erythrocytes,
giving rise to poorly formed and rigid red blood cells as they grow and reproduce.6 Infection
leads to symptoms such as headache, fever, shivering, chills, vomiting, joint pain, and
convulsions within 8 to 25 days.7,8 Plasmodium falciparum, also called malignant malaria, is the
most dangerous form of malaria with the highest rates of morbidity and mortality.9
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Throughout history, there have been many therapeutics to manage and, in some cases,
cure Plasmodium falciparum malaria. Quinine, shown in Figure 1.1, was the first Western
treatment that was effective against Plasmodium falciparum malaria. Starting from the 17th
century, it was the antimalarial of choice until the 1940s. Occurring naturally in the bark of the
Cinchona tree, quinine is the only drug that has remained effective in the treatment of malaria.
As of 2006, the World Health Organization (WHO) suspended quinine as the first-line treatment
for malaria. It is now only used in the treatment of severe malaria or when artemisinins are not
available. 10,11,12,13 The mechanism of action of quinine has not been fully resolved. It has been
hypothesized that it, along with other quinolone antimalarials, act in inhibiting hemozoin
bicrystallization in the heme detoxification pathway. This facilitates the aggregation of cytotoxic
heme, causing heme to accumulate in the parasite which leads to its death.14

Chloroquine, shown in Figure 1.1, is a very effective drug for both the treatment and
prevention of malaria. It was first used in the 1940s after World War II and was very good in
curing all forms of malaria.15 Unfortunately, most strains of falciparum malaria are resistant to
chloroquine which may have come from the drug having been extensively used in mass drug
administrations. Similarly to quinine, chloroquine acts by inhibiting hemozoin bicrystallization
in the heme detoxification pathway. Other than acting as an antimalarial, chloroquine many other
uses. It is used in the treatment of amoebic liver abscess, as an immune system suppressant, and
is being investigated as a retroviral in human HIV-1/AIDS.16,17,18

Mepacrine, shown in Figure 1.1 and also known as both quinacrine and Atabrine, was
developed in the early 1930s and was used on a large scale during World War II. During this
time, it was considered to be a very safe drug, but it is now considered to have too many
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undesirable side effects and is no longer used.15 Its mechanism of action is uncertain, but it is
thought to act against the cell membrane.19 Mepacrine has many medical applications. Not only
is it an antimalarial, but it is also used to treat giardiasis, systemic lupus erythematosus, used as
an intrapleural sclerosing agent, and is also used to treat tapeworm infections.20 It has also been
studied for use as a non-surgical sterilizing agent for women.21

Mefloquine, shown in Figure 1.1, was first introduced in the 1970s, shortly after the end
of the Vietnam War, and is structurally related to quinine. Not only is it used to treat malaria, but
it also is used as a prophylactic antimalarial because of its long half-life.15 It is used to treat
chloroquine-resistant Plasmodium falciparum malaria and is a reasonable alternative for
uncomplicated chloroquine-resistant Plasmodium vivax malaria. However, mefloquine is not
useful against severe malaria.22,23 It is thought to act against malaria in the same way as quinine
and chloroquine. Mefloquine is associated with numerous neuropsychiatric side effects such as
anxiety, hallucinations, depression, dizziness, tinnitus, and suicidal thoughts.24 It also is known
to cause abnormalities in heart rhythms.23,25

Halofantrine, shown in Figure 1.1, was introduced in the 1980s, and it is not structurally
related to quinine. It has a very short half-life, so it is not used as a prophylactic.15 To date, its
mechanism of action is unknown; however, a crystallographic study showed that this compound
binds to hematin in vitro.26 Unlike other antimalarials, halofantrine is only used to treat malaria
and has no other uses. Similarly to mefloquine, halofantrine has many undesirable side effects.
Several neuropsychiatric disturbances have been reported along with abdominal pain, diarrhea,
vomiting, rash, headache, itching, and cardiac arrhythmias.15,27
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Malarone is a drug combination of atovaquone and proguanil, which are shown in Figure
1.1. The combination has been commercially available in the US since 2000. Malarone is used
for both the treatment of malaria and the prevention of malaria; however, proguanil is an
antifolate so caution should be exercised regarding its use as a prophylactic. The drug
combination has undergone many clinical trials, and it was found that this combination is more
than 95% effective against drug resistant falciparum malaria. Although some adverse effects
have occurred, malarone is largely free from undesirable side effects. To date, this drug is very
expensive.15

Quinine

Chloroquine

Mefloquine

Mepacrine

Halofantrine

5

Malarone (atovaquone/proguanil)
Figure 1.1: Structures of antimalarials.

1.2.

ARTEMISININ
Artemisinin is an endoperoxide antimalarial lactone that was derived from qinghao

(Artemisia annua or sweet wormwood). This plant has been used medicinally for over 2,000
years, and in the late 1500s, Li Shizhen recommended qinghao tea to treat malaria symptoms.28
The earliest record of artemisinin being used medicinally dates back to around 200 B.C. in an
unearthed manuscript entitled “Fifty-two Prescriptions”. Its antimalarial application was first
described in “The Handbook of Prescriptions for Emergencies” in the fourth century.29 In 1967,
the Chinese army set up a plant screening research program, Project 523, to find a treatment for
malaria to aid the malaria-stricken North Vietnamese army. Through the course of the research,
artemisinin was discovered in the leaves of the Artemisia annua plant.30, 31

Figure 1.2: The chemical structure of artemisinin (1).

6

Artemisinin and its derivatives (artemether, artesunate, artemotil, dihydroartemisinin,
etc.) possess the most rapid action of all drugs against Plasmodium falciparum malaria.32 Use of
the drug alone is highly discouraged by the World Health Organization (WHO) as this results in
a high rate of parasite return. This could lead to a catastrophic resistance to artemisinin.33
Instead, WHO recommends artemisinin combination therapies (ACTs) as the first line therapy
against Plasmodium falciparum malaria. The artemisinin component kills the majority of the
parasites quickly while the more slowly-eliminated portion clears the rest of the parasites.34
Artemisinin has been found to be active against uncomplicated malaria, severe malaria, certain
cancers, and helminth parasites.35, 36, 37 It is also seeing an increase in use against Plasmodium
vivax malaria.38

1.3.

SERCA/PfATP6
Calcium pumps are calcium ATPases that transport calcium ions across a wide variety of

cellular membranes by using the energy that is obtained from the hydrolysis of ATP. These
pumps are members of the P-type family of ion pumps. The name, P-type, comes from the
mechanism which involves the phosphorylation of a residue in the active site using the terminal
phosphate in ATP. This results in conformational changes in both the ATP-binding domains and
the calcium-binding transmembrane domain which is responsible for shuttling ions across the
membrane.39 Calcium P-type ATPases are categorized into one of two different classes: plasma
membrane Ca2+ ATPases (PMCA) or sarcoplasmic/endoplasmic reticulum Ca2+ ATPases
(SERCA).40

Calcium is used to signal many cellular functions such as muscle contraction and
synaptic transmission. The release of a large amount of free calcium can cause a fertilized egg to
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drop, skeletal muscles to contract, and many other events. Also an elevated calcium level is taken
to signify cell death and triggers the mechanisms of apoptosis. Cells use calcium pumps, or
SERCA pumps, to accumulate calcium in the lumen of the endoplasmic reticulum and
simultaneously regulate cytosolic calcium levels.41 For a cell to use calcium as a signaling
molecule, the cell must first create calcium gradients across its membrane. When a stimulus
signal opens the calcium channels, calcium ions rush into the cytosol signaling muscle
contraction.42 To construct differences in ion concentrations, calcium ions must be actively
pumped across the membrane. These pumps are needed to force the calcium back out of the
cytoplasm returning the cell to its pre-signal state and allowing muscle relaxation. If the calcium
is not forced out of the cytoplasm, the level remains high, and apoptosis commences.39

The structure of SERCA consists of three main parts, which are the cytoplasmic
headpiece, the stalk region, and the transmembrane domain. The cytoplasmic headpiece is
composed of the nucleotide domain (N domain), the phosphorylation domain (P domain), the
hinge region, and the actuator domain (A domain).43 The headpiece is connected to the
transmembrane domain which is comprised of ten alpha helices. While the ATPase is
unphosphorylated, two of the helices form a cavity that is accessible from the cytosol and binds
two calcium ions. ATP binds to a site in the N domain and phosphorylates an aspartate residue in
the adjacent P domain. This causes a conformational change which brings the N and P domains
closer together. This, in turn, results in a 90° rotation of the A domain, causing two of the
transmembrane helices to rearrange. This rearrangement aids in the release of calcium into the
lumen of the sarcoplasmic/endoplasmic reticulum.39

8

Figure 1.3: Representation of SERCA-like proteins showing the P domain, the N domain, the A
domain and the transmembrane domain.

Years ago, a hypothesis was proposed that a SERCA from Plasmodium falciparum,
PfATP6, may be an important target for artemisinin. This was based on biochemical assays
performed on oocytes that heterologously express PfATP6 and on parasite cultures. This is also
based on the fact that PfATP6 is the only SERCA-like protein in the parasite’s genome and that
artemisinins are structurally similar to thapsigargin, a selective, non-competitive inhibitor of
mammalian SERCA.44
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Figure 1.4: Structure of thapsigargin (2).

Thapsigargin, like artemisinin, is a sesquiterpene lactone extracted from a plant, Thapsia
garganica. It works by raising the intracellular cytosolic calcium concentration by blocking the
ability of SERCA to pump calcium out of the cytoplasm and back into the sarcoplasmic
reticulum. This shut down of the pump results in a rapid calcium leak from calcium stores.45 An
antagonistic relationship was observed in the actions of artemisinin and thapsigargin from
isobologram analysis and competition studies, indicating a common target. PfATP6 shares an
overall 40% identity with human SERCA1 but an over 90% identity in the transmembrane
domain. Also, mutation studies on PfATP6 suggested that certain mutations regulate its
sensitivity to artemisinin. For example, in SERCA1, the thapsigargin binding site is near Phe256, and SERCA1 is insensitive to artemisinin. When Leu-263 of PfATP6 was mutated to a
glutamate residue, artemisinin sensitivity decreased, and conversely, when the homologous
glutamate residue in SERCA1, Glu-255, was mutated to a leucine, SERCA1 became sensitive to
artemisinin. These results suggest that PfATP6 is a target for artemisinin.42, 46

1.4

STUDIES OF PfATP6 AND ITS INHIBITORS
Although many research groups have been researching PfATP6, very few inhibitors of

this protein have been reported. Batista, et. al. published the synthesis, cytotoxicity, and
10

antiplasmodial activity of ent-kaurane derivatives. When tested in a cell-based assay, these
compounds exhibited IC50 values ranging from 5.4 to 10.4 µM and very good selectivity indices.
Later, members of the same group took the three most active compounds, shown in Figure 1.6,
and performed rigid and flexible docking studies and binding energy analyses. All three
compounds showed good binding energies against PfATP6, shown in Table 1.1. These data
suggest that PfATP6 is a potential target for diterpene epoxides derived from ent-kauranes, and
further optimization of these lead compounds could provide a more potent and selective
antimalarial.47,48

3

4

5

Figure 1.5: Structures of the three most active diterpene ent-kaurane derivatives.

Table 1.1. Calculated binding energies (kcal/mol) of the three most active diterpene
antiplasmodials.
Compound

Rigid Binding Energy

Flexible Binding Energy

3

-7.7

-6.6

4

-7.8

-6.3

5

-8.4

-6.8
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Curcumin, a yellow spice found in the root of Curcuma longa, is a beta-diketone and has
been used to cure diseases such as jaundice, indigestion, urinary tract diseases, rheumatoid
arthritis, insect bites, and cancer. Curcumin was found to act synergistically with artemisinin
against Plasmodium berghei and can also serve as a potent inhibitor against chloroquine-resistant
Plasmodium falciparum. However, its mechanism is not fully elucidated yet. To examine the
possibility of curcumin analogs as ligands for PfATP6, 351 curcumin derivatives from the ZINC
database were docked into a homology model of PfATP6 using two different docking programs.
Docking results showed that more than 50 curcumin analogs can bind to PfATP6 with similar, or
better, affinity than curcumin itself. One compound, ZINC05606394, was predicted to bind
better than curcumin by both docking programs.49

Figure 1.6: Structures of curcumin (6, left) and the curcumin analog, ZINC05606394.

Table 1.2: Glide docking scores and FlexX docking scores of curcumin and its analogs.49
Compound

Glide score

Compound

FlexX score

ZINC13781298

-7.890

ZINC49111530

-19.8003

ZINC49881409

-7.878

ZINC05606394

-19.2761

ZINC44281717

-7.796

ZINC28955244

-18.2869

ZINC05606394

-7.775

ZINC35050563

-15.8370

ZINC13781298

-7.755

ZINC00899824

-15.2578

ZINC49124982

-7.669

ZINC28955244

-13.9284

curcumin

-6.753

curcumin

-13.9685
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Uhlemann, et. al. studied the possible mechanism of action of a fully synthetic peroxidic
antimalarial, RBX11160 (OZ277). In this compound, the crucial peroxidic pharmacophore of the
artemisinins is present within a 1,2,4-trioxane heterocycle. Since they have this feature in
common, the group tested the idea that RBX11160 may also specifically inhibit PfATP6. Several
experiments were performed including ATPase assays, Plasmodium falciparum hexose
transporter (PfHT) glucose reuptake experiments, culturing of parasites and isobolograms, and
immunofluorescence microscopy.50

Figure 1.7: Structure of RBX11160. (7)

Figure 1.8: Apparent inhibitory constants for PfATP6 of RBX11160 and artemisinin. The
apparent Ki values are 7,700 nM for RBX11160 (filled circles) (n = 3 for each value) and 79 nM
for artemisinin (filled squares) (n = 5 for each value). (Figure duplicated with permission from
Dr. Sanjeev Krishna of St. George’s University of London.)50

13

Figure 1.9: RBX11160 inhibition of transporter activities. (a) Inhibition of PfATP6 activity by
RBX11160 (50 µM) compared with results for control preparations (n = 6 for both groups; P =
0.0018). (b) Inhibition of mammalian SERCA by RBX11160 (100 µM; P = 0.13) and
thapsigargin (10 µM; P = 0.0007) compared with results for control experiments. (c) Uptake of
D-glucose in water-injected (diethyl pyrocarbonate [DEPC]) and PfHT-expressing oocytes is
shown. There is no inhibition of PfHT activity by RBX11160 (50 µM, n ≥ 9 per column; P >
0.5). DMSO, dimethyl sulfoxide. (Figure duplicated with permission from Dr. Sanjeev Krishna
of St. George’s University of London.)50

Figure 1.10: Isobologram of RBX11160 and artesunate. Points lying above the line of additivity
indicate antagonistic effects. The summed fractional inhibitory concentration index (FIC) for this
assay [geometric mean (range)] is 2.4 (1.85 to 4.2). (Figure duplicated with permission from Dr.
Sanjeev Krishna of St. George’s University of London.)50
14

RBX11160 inhibits PfATP6 with an IC50 of 7,700 nM, almost one hundred times less
potently than artemisinin. However, all the data demonstrate that there are similarities and
differences between RBX11160 and the semisynthetic antimalarials such as artemisinin and its
derivatives.50

Bousejra-El Garah, et. al. divided antimalarial compounds into two groups based on their
chemical structures and their reactivities towards iron. The two groups were peroxide-containing
drugs and quinolone-based drugs. The peroxide-containing compounds used were artemisinin
derivatives, 1,2,4-trioxane, 1,2,4-trioxolane, and 1,2,4,5-tetraoxane derivatives. The quinolonebased compounds used were chloroquine derivatives, quinine, and mefloquine. Trioxaquines,
which are hybrid molecules with a dual mechanism of action, were also studied for comparison.
The predicted binding affinities of these compounds with PfATP6 were evaluated using their
binding free energies (Ebind kcal/mol) and inhibition constants (Ki, µM). The group concluded
that the predicted binding affinities of these compounds for PfATP6 do not correlate with either
their antimalarial activity or the reported inhibition of the protein.51

Artemisinin derivatives

R=
(8) Artemisinin R=O
(9) DHA R=OH

R=

(10) Artemisone
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(11) MP118

R=
Artemisinin-acridine derivative (12)

Deoxyartemisinin (13)

Figure 1.11: Artemisinin derivatives used in the study in reference #51.

Trioxolanes and Tetraoxane

OZ277 (14)

carba-OZ277 (15)

RKA216 (16)
Figure 1.12: Trioxolane derivatives used in the study in reference #51.
Trioxaquines

DU1301 (17)

DU1302 (18)
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PA1103 (19)
Figure 1.13: Trioxaquines used in the study in reference #51.
Quinolines

Chloroquine (20)

21

Quinine (23)
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Mefloquine (24)

Figure 1.14: Quinoline-based compounds used in the study in reference #51.

David-Bosne, et. al. performed an investigation that focused on purifying PfATP6 on a
large scale and maintaining its enzymatic activity. They then tested classical SERCA1a
inhibitors such as cyclopiazonic acid (CPA) to determine their ability to inhibit parasite growth.
They wanted to test whether there is a correlation between the enzymatic inhibition of PfATP6
and their antiplasmodial activity results. They then ran a test to measure inorganic phosphate
17

liberation to screen several compounds. The IC50 values for the inhibition of PfATP6 ATPase
activity were determined for 1,680 compounds. Twenty of these compounds exhibited potent
inhibitory effects with IC50 values less than 10 µM. Eight compounds were selected based on
their ability to inhibit the growth of the FcB1 and 3D7 strains of Plasmodium falciparum. The
group eventually concluded that there is no correlation between the inhibition of PfATP6 activity
and the antiplasmodial activity of the compounds. They found that compounds can exhibit
PfATP6 activity in vitro but possess limited antiplasmodial activity and vice versa.52

25

26

28

29

31

27

30

32

Figure 1.15: Structures of the compounds that were identified to be potent inhibitors of PfATP6.
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Table 1.3: Effect of SERCA classical inhibitors upon Plasmodium falciparum growth in vitro.
IC50 PfATP6: values of the inhibition of the ATPase activity determined on the purified PfATP6.
Indication of the IC50 values for each drug on two P. falciparum laboratory strains differently
resistant to chloroquine (3D7 and FcB1). Values (µM) correspond to at least three biological
replicates. ND= not determined.52
Compound

IC50 PfATP6

IC50 FcB1

IC50 3D7

Thapsigargin

150

6.1 ± 1.05

11.5 ± 5.7

BHQ

65

17.2 ± 11.3

30.6 ± 13.5

CPA

0.4

4.9 ± 0.9

8.8 ± 3.4

Chloroquine

ND

0.13 ± 0.02

0.012 ± 0.002

Table 1.4: IC50 of the compounds identified to be potent inhibitors of PfATP6 and chosen to be
tested on P. falciparum cultures. IC50 PfATP6: values of the inhibition of the ATPase activity
determined on the purified PfATP6; IC50 FcB1/IC50 3D7: effect of the identified PfATP6
inhibitors on two P. falciparum strains differently resistant to chloroquine (3D7 and FcB1).
Values (µM) correspond to at least three biological replicates.52
Compound

IC50 PfATP6

IC50 FcB1

IC50 3D7

25

3.0 ± 2.2

71 ± 25

108 ± 8

26

1.1 ± 0.5

57 ± 15.8

53 ± 19

27

3.1 ± 1.0

88 ± 33

91.5± 16

28

1.2 ± 0.6

169 ± 17

241 ± 19

29

1.0 ± 0.6

6.2 ± 1.7

4.9 ± 2.1

30

1.0 ± 0.6

2.3 ± 1.2

3.1 ± 1.2

31

8.5 ± 1.6

14.3 ± 3.6

14.8 ± 7.7

32

7.0 ± 5.4

61 ± 26

62 ± 26

The topic of artemisinin is not an unfamiliar one to our research group. Previously in our
group, Sun, et. al., focused their attention on using the natural product sesquiterpene,
thapsigargin, as a potential lead compound for drug discovery. Thapsigargin belongs to the
19

guaianolide class of sesquiterpenes, and as mentioned before, it is a highly potent and specific
irreversible SERCA inhibitor. It also moderately inhibits PfATP6. While attempting to
synthesize thapsigargin, a precursor, 33, was designed and named thaperoxide. This compound
showed striking similarities to both artemisinin and thapsigargin. Derivatives of thaperoxide
were synthesized to derive a structure-activity relationship (SAR). The activities of these
derivatives were evaluated and compared to the activities of both artemisinin and thapsigargin.53
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39
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37

40
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38

41

42
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48

47

49
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51

52

Figure 1.16: Structures of the guaianolide-endoperoxides that were synthesized and tested in
reference #51.

21

Table 1.5: Antimalarial Activity against W2 Clones of P. falciparum
Compound no.

IC50 (µM)

Compound no.

IC50 (µM)

33

0.29 ± 0.01

44

0.23 ± 0.09

34

9.11 ± 0.21

45

0.57 ± 0.04

35

NA

46

0.37 ± 0.00

36

NA

47

0.61 ± 0.03

37

NA

48

0.27 ± 0.02

38

NA

49

NA

39

4.60 ± 0.10

50

3.40 ± 0.87

40

1.05 ± 0.00

51

0.024 ± 0.02

41

1.04 ± 0.01

52

7.50 ± 0.04

42

0.62 ± 0.02

artemisinin

0.005 ± 0.00

43

0.013 ± 0.000

thapsigargin

9.92 ± 0.10

NA = not active up to 10 µM
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CHAPTER 2. PREVIOUSLY PROPOSED MECHANISMS
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As previously mentioned, artemisinins contain an endoperoxide bridge that is absolutely
crucial for their antimalarial activity. However, exactly how this endoperoxide bridge aids in
killing the parasite is still a controversial subject. Theories have emerged over the years ranging
from an artemisinin-heme interaction in the parasite that generates carbon-centered radicals to
the inhibition of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase inside the parasite. All
will be discussed.

2.1.

HEME MECHANISM
A portion of the life cycle of Plasmodium falciparum, as stated earlier, occurs in the

erythrocyte, or red blood cell, of a human host. It is during this stage that hemoglobin is utilized
by the parasite as a food source. The hemoglobin is then taken into the food vacuole and broken
down by proteolytic enzymes called plasmepsins. The broken down hemoglobin is further
degraded into amino acids by food vacuole cysteine proteases known as falcipains.54,55

The proposed heme mechanism is that hematin, which is ferric protoporphyrin IX or
Fe(III)PPIX, upon reduction to heme, or Fe(II)PPIX, is the source of ferrous iron that is
responsible for bioactivation of the endoperoxide bridge of artemisinin to cytotoxic radical
species. Artemisinin-mediated oxidative stress is the proposed mechanism of action based on in
vitro experiments with infected red blood cells or parasite membranes. Heme catalyzes the
reductive decomposition of artemisinin, and artemisinin was shown to increase the
methemoglobin concentration and to slightly reduce the glutathione and membrane fatty acid
concentrations which result in a dose-dependent increase of cell lysis.55 The possible mechanism
is depicted in Scheme 2.1. Further studies with Mn instead of Fe porphyrin led to isolable C4
adducts to the porphyrin ring system shown in Figure 2.1.56
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Scheme 2.1: The possible mechanism for the artemisinin mediated lipid peroxidation of cell
membranes.

Lipid solubilized heme interacts with artemisinin followed by ferrous-mediated
generation of oxygen and carbon radicals. These radicals are in the vicinity of target allylic
hydrogens of unsaturated lipid bilayers. Hydrogen radical formation followed by oxygen capture
results in the formation of lipid hydroperoxides. Fenton cleavage of the hydroperoxide forms
reactive oxygen species such as hydroxyl radicals and superoxide which is thought to be the
cause of damage to the food vacuole membrane. This damage leads to vacuolar rupture and
parasite autodigestion. However, numerous workers in the field have proposed that parasite death
is probably not caused by random cell damage from freely diffusing reactive oxygen species, but
may involve specific radicals and targets.55
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Figure 2.1: Isolated reaction products of artemisinin with manganoporphyrin.

2.2.

CARBON RADICALS MECHANISM
The free radical chemistry of artemisinin is very well defined and has been shown to

involve an initial chemical decomposition induced by ferrous ions within the malaria parasite.
This produces an oxygen radical initially but subsequently rearranges into one or both of two
distinctive carbon-centered radicals. Scheme 2.2 shows the main radical pathways for
artemisinin following endoperoxide-mediated bioactivation.55
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Scheme 2.2: Proposed mechanism of the in vitro reaction of artemisinin with FeII.

Since artemisinin (1) is an asymmetric endoperoxide, the peroxide oxygens can interact
with ferrous ions in two ways: through O1 or through O2. Association through O1 produces an
oxygen radical 2 that goes on to become a primary carbon radical 3. This radical is then thought
to be scavenged by molecules such as heme or gluthione to create the corresponding adducts.
Association through O2 provides an oxygen radical 5 that produces a secondary carbon radical 6
via a 1,5-H shift. The final product is the stable hydroxydeoxoartemisinin 9. It has been proposed
that alkylation by the radical intermediates of biomacromolecules results in the death of the
malarial parasite.55 It has also been suggested that the non-isolable epoxide 8 was responsible
for protein alkylation, but total synthesis of 13-carba-artemisinin by Avery, et al led to a stable

27

epoxide that was without activity, yet its peroxy precursor was of similar potency to artemisinin
(cf. Figure 2.2).57

Figure 2.2: Activities of peroxidic and non-peroxidic derivatives of artemisinin.

These studies clearly show that the epoxide proposed by Posner, compound 8 (Scheme
2.2), is an unlikely intermediate that, even if it did form, would not be essential for activity.

2.3.

CYSTEINE MECHANISM
Following the pioneering work of Meshnick and Posner, the cleavage theory could not be

further developed because there was no logical link between the death of the parasite and the
damage occurring to free heme since it is not essential to the life of the parasite. Wu et.al.
reported that non-heme iron in the presence of cysteine can also cleave artemisinin efficiently,
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and the transient carbon radical formed can covalently bind to the ligand at iron through a sulfur
atom.58
Under near physiological conditions, FeII plays a negligible role. However, free FeII ions
may form complexes with amino acids and be greatly activated. For instance, in the presence of
cysteine, artemisinin can be degraded quite rapidly. It was believed that the catabolism of
hemoglobin causes a higher concentration of free amino acids in infected erythrocytes than in
uninfected erythrocytes, and the malaria parasite has a high concentration of reduced glutathione
which is the main sulfhydryl-containing reducing agent in physiological systems. This was the
first piece of established evidence for intermolecular interactions involving artemisinin.58

Scheme 2.3: Acetate elimination mediated by a thiol.

9

10

11

Scheme 2.3 shows how the carbon radical formed from the FeII association with O1
interacts with a thiol such as in cysteine and then eliminates an acetate. The formation of 11
provides unequivocal evidence for the involvement of the highly reactive primary radical 9. They
envisaged that 9 may intramolecularly attack the cysteine sulfur atom complexed to the FeIII ion
and release an FeII ion. The product resulting from such an attack after degradation leads to
structure 13 as shown in Scheme 2.4.58
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Scheme 2.4: Intramolecular attack of a cysteine sulfur to form a complex.
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13

The importance of the concatenation of artemisinin and cysteine observed here in this
simple chemical model system lies in the precise mechanistic basis it offered at the molecular
level for the radical-mediated alkylation of proteins. Such a basis had been missing in all
documented investigations to date.58 Although mechanistically pleasing, the difficulty with this
mechanism is that a covalent adduct of cysteine to Fe(II) is required. Under physiological
conditions, formation of Fe(II)-SR compounds are implausible thermodynamically and even
intuitively; if cysteine thiols or other biological thiols were susceptible to formation of covalent
bonds, mammals would act as Fe(II) scavengers shutting down biochemical pathways, and the
food we eat would be a deadly poison. A more complicated mechanism is therefore more likely
to be involved that we will discuss shortly.

2.4.

COFACTOR MECHANISM
Haynes et.al. conducted many experiments to point to the unlikelihood of carbon radicals

or heme triggering the antimalarial activity of artemisinin and adopted a rather different
approach to the consideration of the mechanism of action. The antimalarial methylene blue
works by affecting the redox behavior of parasite flavin-dependent disulfide reductases such as
glutathione reductase that control oxidative stress in the parasite. The synergism observed
30

between methylene blue and the artemisinin derivative artesunate suggests a complementary
mode of action.59

Scheme 2.5: The ascorbic acid and methylene blue transformation of artemisinin.

From the proposed scheme, we see that Haynes found that artemisinins are transformed
by leucomethylene blue which is generated from methylene blue and ascorbic acid in situ in
aqueous buffer at physiological pH into single electron transfer (SET) or two electron reduction
rearrangement products. A ketyl arose that was oxidized to the carbonyl. Since artemisinins
generate reactive oxygen species and behave synergistically with methylene blue and
doxorubicin, they concluded that artemisinins act as electron acceptors and are likely to interfere
with redox-active cofactors such as flavoenzymes.59
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2.5.

SERCA/PfATP6 MECHANISM
As discussed under preceding hypotheses, studies have suggested that artemisinin acts by

heme-dependent activation of the endoperoxide bridge occurring within the food vacuole.
However, localization of artemisinin to parasite and not food vacuole membranes and the fact
that artemisinin can effectively kill the ring stage of the parasite even though it lacks hemazoin
argue against the food vacuole being a major site for drug action. Krishna et.al. discovered that
artemisinin shows structural similarities to thapsigargin, a highly specific inhibitor of
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA). They proceeded to hypothesize that when
activated, artemisinin acts by specifically and selectively inhibiting PfATP6, the only SERCAtype CA2+-ATPase sequence in Plasmodium falciparum.44

PfATP6 was expressed in Xenopus laevis oocytes. It was found to be inhibited not only
by artemisinin, but also by thapsigargin and another mammalian SERCA inhibitor, cyclopiazonic
acid. They then assessed the inhibitory properties of chloroquine, quinine, and artemisinin on
transporter proteins encoded by P. falciparum as well as their effects on SERCA1a. None of
these structurally diverse compounds interferes non-specifically with the function of integral
membrane proteins of P. falciparum. SERCA1a activity was also not affected by these
compounds.44
PfATP4 is the only other Ca2+-ATPase-like sequence identified in the P. falciparum
genome and defines a non-SERCA subclass of Ca2+-ATPase unique to apicomplexan organisms.
The antimalarials tested also did not inhibit the activity of PfATP4. The Ca2+-ATPase activity of
PfATP6 was inhibited by artemisinin but not by chloroquine or quinine. Even at relatively high
concentrations, artemisinin inhibits PfATP6 with high specificity. Endogenous Ca2+-ATPase
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activity is also resistant to the action of artemisinin, which demonstrates the unique specificity of
artemisinin for PfATP6.44

The interactions of artemisinin and thapsigargin with PfATP6 were compared by
measuring their inhibitory constants. Thapsigargin irreversibly inhibited Ca2+-ATPase activity
with 1:1 stoichiometry, and the inhibitory profile of artemisinin was directly superimposable
over that of thapsigargin, showing that they inhibit PfATP6 with the same potency and
stoichiometry in vitro.44

Since both thapsigargin and artemisinin specifically inhibit PfATP6, Krishna et.al. went
on to predict that they would exhibit mutual antagonism in cultured parasites. They were
administered simultaneously in varying concentrations. As predicted, thapsigargin antagonized
the parasiticidal activity of artemisinin. The two drugs show significant antagonism indicating
that artemisinin specifically inhibits PfATP6 in intact parasites. To confirm that PfATP6 is the
target for artemisinins, they compared inhibitory constants of a range of artemisinin derivatives
such as dihydroartemisinin, artesunate, artemether, artemotil, and arteflene against PfATP6 in
oocytes with their ability to kill parasites in vitro. Almost perfect correlations existed between
the inhibitory potencies and the IC50 values from cultured parasites. To confirm that ferrous ions
are indeed necessary for artemisinin’s antimalarial activity, desoxyartemisinin, artemisinin
without the endoperoxide bridge, was assayed and found to be inactive against PfATP6.
Chelation of iron by desferrioxamine abrogates the antiparasitic activity of artemisinins. These
studies support PfATP6 as a target of artemisinin, and it likely operates via an Fe2+-dependent
activation mechanism. This allowed, for the first time, rational biological target-guided drug
design efforts to be carried out.44
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CHAPTER 3. DEVELOPMENT OF A HYBRID MECHANISM

*Shuneize E. Slater, Jakub Kollar, Kuldeep K. Roy, Khaled M. Elokely, Sanjeev Krishna,
Robert J. Doerksen, Mitchell A. Avery, Unpublished.
34

3.1

INTRODUCTION
After studying all of the previously proposed mechanisms of action, we began sifting

through them to determine which was more feasible. However, we discovered that each
mechanism was flawed for various reasons. The alkylation of heme was not acceptable as heme
is not important to the survival of the parasite, and carbon radicals did not completely answer the
question as random alkylation of biomolecules seemed far-fetched. The SERCA and cysteine
hypotheses finally gave a specific target for artemisinin, but they give no further explanation of
what happens after radical extraction. The two that caught our attention the most were the
SERCA and the cysteine hypotheses, so we developed the PfATP6/ferrous ion/cysteine
hypothesis, otherwise known as the Hybrid SERCA hypothesis.

Our current hypothesis was not our first, however. Our first hypothesis suggested that a
cysteine thiol moiety in the protein is able to recruit a ferrous ion as it is “passing by”. The
ferrous ion then ligates the endoperoxide bridge of artemisinin. This would be possible in any of
ten different locations. This hypothesis relieves us of finding a ferrous ion binding site and also
of finding an artemisinin binding site as both are recruited when in the vicinity of the cysteine
thiol. We abandoned that hypothesis as it would not be computationally efficient to examine
every cysteine in the protein. We then hypothesized that a ferrous ion finds a binding site near a
cysteine residue. The ion then ligates the endoperoxide bridge of artemisinin as it approaches.
We looked, particularly, at the two calcium ions in the channel. Thinking that the calcium ions
could exchange for the ferrous ions, we examined the pocket. We found that there are no
cysteine residues near the calcium ion binding sites, and also the ferrous ions are not able to be
coordinated by the same residues as the calcium ions. So this hypothesis, too, was discarded.
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In our third hypothesis, we predicted that artemisinin would bind in its binding site
somewhere near a cysteine residue. The endoperoxide bridge of artemisinin would then ligate the
ferrous ion as it approaches. In this scenario, only artemisinin is required to have a binding site.
In the final hypothesis, both artemisinin and the ferrous ion bind in their respective binding sites
near a cysteine residue. Since the last two hypotheses seem more feasible, these are the two that
we decided to investigate further.

Figure 3.1: The optimal synchronous reaction that occurs between iron, artemisinin, and the
cysteine residue of PfATP6.

Figure 3.1 shows the importance of the orientation of the iron atom, the cysteine residue,
and the peroxide bridge of artemisinin. The reaction that occurs between artemisinin and PfATP6
is more than likely a synchronous reaction; however, it may occur in 2 steps. Either way, there
are certain distances between the three components that need to be obtained. Once Fe2+ cleaves
the peroxide bridge of artemisinin, a short-lived oxygen radical forms and quickly rearranges to a
carbon radical. Carbon radicals are also extremely short-lived. Intramolecular destruction will
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commence, and this leads to neutral products. Therefore, the geometry and the distances between
the atoms are so significant.

Figure 3.2: Mechanism of action of our third hypothesis.

Figure 3.2 represents our third hypothesis. Artemisinin comes in and binds in its binding
site near a cysteine residue. The ferrous ion is recruited and then ligates the endoperoxide bridge
of artemisinin. Cleavage of the bridge effects an oxygen radical that rearranges to a carbon
centered radical. This radical is in close proximity to the cysteine thiol moiety and is captured. A
covalent sulfide bond is formed between the protein and artemisinin thus shutting down the
calcium pump and leading to the death of the parasite.
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Figure 3.3: Details of Putative Mechanism of our fourth hypothesis.

Figure 3.3 represents our fourth hypothesis. The ferrous ion binds in its binding site near
a cysteine residue. Artemisinin comes in and binds in its binding site nearby. The ferrous ion
then ligates the endoperoxide bridge. Cleavage of the bridge effects an oxygen radical that
rearranges to a carbon centered radical. This radical is in close proximity to the cysteine thiol
moiety and is captured. A covalent sulfide bond is formed between the protein and artemisinin
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thus shutting down the calcium pump and leading to the death of the parasite. We have
exhausted many computational tools to test the likelihood of our hypotheses, and they will all be
discussed thoroughly.

3.2

STRUCTURE MODELING AND VALIDATION
Protein structure modeling, or protein structure prediction, is the prediction of a protein’s

folding and its secondary, tertiary, and quaternary structure from its primary structure or amino
acid sequence. Structure modeling is one of the most important goals pursued by bioinformatics
and is very important in drug design. Protein structure prediction is now more significant than
ever. There is a huge amount of protein sequence data produced by modern large-scale DNA
sequencing efforts such as the Human Genome Project. X-ray crystallography and NMR
spectroscopy produce protein structures but are typically time-consuming and expensive and lag
far behind the output of protein sequences.60

The two major problems facing protein structure prediction are the calculation of protein
free energy and finding the global energy minimum. Comparative protein modeling can partially
bypass these issues. Although the number of proteins is vast, there is only a limited set of tertiary
structural motifs to which most proteins belong. Comparative modeling uses previously solved
protein structures as starting points, or templates.61

Homology modeling, which is a type of comparative modeling, is based on the fact that a
protein’s fold is more evolutionarily conserved than its amino acid sequence. This allows a target
sequence to be modeled with reasonable accuracy from a very distantly related template;
however, homology modeling is most accurate when the target and template have similar
sequences.61
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The 1,228 amino acid sequence of Plasmodium falciparum ATPase 6 (PfATP6) was
obtained from the Plasmo Database (PlasmoDB) website and is as follows:

MEEVIKNAHTYDVEDVLKFLDVNKDNGLKNEELDDRRLKYGLNELEVEKKKSIFELILN
QFDDLLVKILLLAAFISFVLTLLDMKHKKIEICDFIEPLVIVLILILNAAVGVWQECNAEKS
LEALKELQPTKAKVLRDGKWEIIDSKYLYVGDIIELSVGNKTPADARIIKIYSTSLKVEQS
MLTGESCSVDKYAEKMEDSYKNCEIQLKKNILFSSTAIVCGRCIAVVINIGMKTEIGHIQH
AVIESNSEDTQTPLQIKIDLFGQQLSKIIFVICVTVWIINFKHFSDPIHGSFLYGCLYYFKIS
VALAVAAIPEGLPAVITTCLALGTRRMVKKNAIVRKLQSVETLGCTTVICSDKTGTLTTN
QMTTTVFHLFRESDSLTEYQLCQKGDTYYFYESSNLTNDIYAGESSFFNKLKDEGNVEA
LTDDGEEGSIDEADPYSDYFSSDSKKMKNDLNNNNNNNNNSSRSGAKRNIPLKEMKSN
ENTIISRGSKILEDKINKYCYSEYDYNFYMCLVNCNEANIFCNDNSQIVKKFGDSTELALL
HFVHNFDILPTFSKNNKMPAEYEKNTTPVQSSNKKDKSPRGINKFFSSKNDNSHITSTLN
ENDKNLKNANHSNYTTAQATTNGYEAIGENTFEHGTSFENCFHSKLGNKINTTSTHNNN
NNNNNNSNSVPSECISSWRNECKQIKIIEFTRERKLMSVIVENKKKEIILYCKGAPENIIKN
CKYYLTKNDIRPLNETLKNEIHNKIQNMGKRALRTLSFAYKKLSSKDLNIKNTDDYYKL
EQDLIYLGGLGIIDPPRKYVGRAIRLCHMAGIRVFMITGDNINTARAIAKEINILNKNEGD
DEKDNYTNNKNTQICCYNGREFEDFSLEKQKHILKNTPRIVFCRTEPKHKKQIVKVLKDL
GETVAMTGDGVNDAPALKSADIGIAMGINGTEVAKEASDIVLADDNFNTIVEAIKEGRCI
YNNMKAFIRYLISSNIGEVASIFITALLGIPDSLAPVQLLWVNLVTDGLPATALGFNPPEH
DVMKCKPRHKNDNLINGLTLLRYIIIGTYVGIATVSIFVYWFLFYPDSDMHTLINFYQLSH
YNQCKAWNNFRVNKVYDMSEDHCSYFSAGKIKASTLSLSVLVLIEMFNALNALSEYNS
LFEIPPWRNMYLVLATIGSLLLHVLILYIPPLARIFGVVPLSAYDWFLVFLWSFPVIILDEII
KFYAKRKLKEEQRTKKIKID
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The sequence was then aligned with a 2.4 Ångstrom resolution crystal structure of human
calcium ATPase (PDBID: 2AGV) using ClustalW. The alignment was then visually inspected
and manually altered to match the alignment obtained by Prime62, which is the protein structure
prediction module of Schrödinger. The final alignment was used as an input for the building of
100 homology models of PfATP6 using Modeller version 9.12 software. After the 100 models
were generated they underwent loop refinement, and their Ramachandran plots were analyzed to
find the models with the least number of outliers. Six models (Model 3, Model 4, Model 10,
Model 11, Model 13, and Model 44) were chosen to be saved as pdb files, uploaded into the
Maestro62 workspace, which is the visual interface for all of Schrödinger’s applications, and
prepared and minimized using the Protein Preparation Wizard62 default procedure which is as
follows: the bond orders were assigned, hydrogens were added, zero-order bonds were created to
metals, disulfide bridges were formed, waters beyond 5 Å from het groups were deleted, noncoordinated water molecules and all het groups other than thapsigargin were deleted, and finally
the protein was minimized.
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Figure 3.4: Sequence alignment of PfATP6 and 2AGV.
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Figure 3.5: After Modeller homology modeling and loop refinement, the complete structure of
Model 3 emerged as is shown here in red.

Figure 3.6: The Ramachandran plot for Model 3 shows that 93.7% of the residues are in the
favored region, 4.8% of the residues are in the allowed region, and only 1.6% of the residues are
in the outlier region.
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Figure 3.7: After Modeller homology modeling and loop refinement, the complete structure of
Model 4 emerged as is shown here in aquamarine.

Figure 3.8: The Ramachandran plot for Model 4 shows that 94.1% of the residues are in the
favored region, 4.6% of the residues are in the allowed region, and only 1.4% of the residues are
in the outlier region.
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Figure 3.9: After Modeller homology modeling and loop refinement, the complete structure of
Model 10 emerged as is shown here in magenta.

Figure 3.10: The Ramachandran plot for Model 10 shows that 94.9% of the residues are in the
favored region, 3.6% of the residues are in the allowed region, and only 1.6% of the residues are
in the outlier region.
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Figure 3.11: After Modeller homology modeling and loop refinement, the complete structure of
Model 11 emerged as is shown here in yellow.

Figure 3.12: The Ramachandran plot for Model 11 shows that 94.2% of the residues are in the
favored region, 4.3% of the residues are in the allowed region, and only 1.6% of the residues are
in the outlier region.
46

Figure 3.13: After Modeller homology modeling and loop refinement, the complete structure of
Model 13 emerged as is shown here in peach.

Figure 3.14: The Ramachandran plot for Model 13 shows that 94.5% of the residues are in the
favored region, 3.9% of the residues are in the allowed region, and only 1.7% of the residues are
in the outlier region.
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Figure 3.15: After Modeller homology modeling and loop refinement, the complete structure of
Model 44 emerged as is shown here in gray.

Figure 3.16: The Ramachandran plot for Model 44 shows that 94.6% of the residues are in the
favored region, 4.2% of the residues are in the allowed region, and only 1.3% of the residues are
in the outlier region.
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To determine the validity of the Modeller models, the six prepared and minimized models
were used to generate receptor grids of the active sites using the default options available in
Glide62, which is a docking program in the Schrödinger suite. The co-crystallized ligand,
thapsigargin, was used to indicate the active site. After the grids were generated, artemisinin,
thapsigargin, and the thaperoxides were drawn in the Maestro workspace, then submitted to
MacroModel62 for conformational searches. MacroModel is a module of the Schrödinger suite. It
combines force fields, solvation models, and an advanced conformational searching method to
comprise an advanced and complete molecular modeling package. A total of 855 conformers
were created and then docked both flexibly and rigidly into the active site of all of the models
using Glide. After many tries including using positional constraints to bias the tricyclic core to
the phenylalanine in the active site, no correlation could be detected between the biological
activities and docking scores. We drew an assumption that using the extremely large ligand,
thapsigargin, to indicate the active site was causing all the small molecules to fit into the active
site posing an inability to properly rank the compounds. So the six models were again prepared
and minimized, but this time all co-crystallized ligands were deleted. Receptor grids of the active
sites were then generated by specifying residues Leu263, Phe264, Gln267, Ile977, Ile981,
Asn1039, Leu1040, Ile1041, and Asn1042. Also realizing that the thaperoxide compounds had
only undergone a cell-based assay and not a PfATP6 target-based assay, we decided to use the
eight compounds assayed by David-Bosne et.al. that were proven to have PfATP6 inhibitory
activity in a target-based assay as test compounds. These eight compounds were drawn and
minimized in the Maestro workspace for visualization. The compounds were then submitted to
MacroModel conformational search. 1,488 conformers were generated and then docked into the

49

active sites using Glide. However, no significant correlation could be found between the docking
scores and the reported biological activities.

Prime was also used to construct a homology model of PfATP6. In the homology model
building panel, the PfATP6 sequence was pasted into the text box, and a BLAST homology
search was initiated to find homologous proteins. PDBID 1SU4, having an overall 44% identity
with the input sequence, was selected as the template. ClustalW was then used to align the two
sequences. An energy-based building method was selected because it is more accurate than the
knowledge-based method. The two bound calcium ions in the channel were chosen to be
included in the model. Loop refinement was not performed. This procedure produced four
models. To determine their validity, the Prime models were prepared and minimized in the same
manner as the Modeller predicted models. Receptor grids were made of the active sites of the
models by specifying Leu263, Phe264, Gln267, Ile977, Ile981, Asn1039, Leu1040, Ile1041, and
Asn1042. The 1,488 conformers of the eight PfATP6 inhibitors were then docked into the grids
using Glide docking. The fourth model was able to identify the four most active compounds and
the least active compound and ranked them accordingly. So this was the model chosen for further
studies and experimentation.
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Figure 3.17: The fourth and best model predicted by Prime shown in green, also showing the
bound calcium ions in the channel.

3.3

PROTEIN POCKET DETECTION
Predicting functional sites in protein structures such as ligand binding sites or catalytic

sites is very important. It largely relies on the identification and characterization of clefts and
cavities in the protein structure, and it can guide the design of small molecules that could interact
with a protein and modulate its activity and function. Many online services have been proposed
for pocket detection. The fpocket protein pocket detection program was introduced a few years
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ago and was found to be able to correctly identify more than 90% of known binding sites in both
holo and apo proteins. It also ranks the sites found in the protein based on their “druggability”.63
The validated PfATP6 model was uploaded, and fpocket was executed. After concluding, 51
pockets were found in the protein.

Figure 3.18: Model of PfATP6 showing the 51 pockets (in various colors and different sized
spheres) found by fpocket.
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3.4

BLIND DOCKING
Blind docking is used when only the structure of the macromolecule or protein and the

structure of the ligand are known. There is no prior knowledge of the binding site. This
application is named blind docking because the docking algorithm is not able to “see” the
binding site but can still find it.64

The most important requirement of a blind docking calculation is its ability to distinguish
between the actual binding site and nonspecific and/or energetically unfavorable sites. AutoDock
packages have been proven to be efficient and robust at finding binding pockets and binding
orientations of ligands. This makes this program particularly attractive because one method can
be used to search for the binding site and to accurately dock the ligands.64

Since the AutoDock packages have been recognized for their ability not only to identify
the binding site of ligands but also to dock the ligands well, we decided to use AutoDock Vina to
identify all of the artemisinin binding sites in PfATP6. The structure of artemisinin was drawn
and minimized in the Maestro workspace and then saved as a pdb file. The pdb file of the
PfATP6 homology model was uploaded into AutoDock Vina. Hydrogens were added, and the
protein was saved as a pdbqt file. A grid box of the protein was created to tell the program where
to dock the ligand. Since this is blind docking, the entire protein structure was included in the
grid box. The minimized structure of artemisinin was then uploaded to AutoDock Vina and
saved as a pdbqt file. Torsions were not required as there are no rotatable bonds in artemisinin. A
text file was used to identify the protein, ligand, grid box, grid spacing, and the exhaustiveness of
the program. The command prompt was used to run the docking algorithm using a specified
input text file. Nine results were obtained, but only 4 artemisinin binding sites were found.
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Interestingly, these four sites were the sites ranked the most druggable by the fpocket pocket
searching software. These sites were then extensively analyzed.

Figure 3.19: These are the four pockets that AutoDock Vina found that are able to be
artemisinin binding sites, shown as white, red, blue, and yellow spheres.
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Two of the pockets have been explored previously, as the pocket indicated by the red
spheres is the thapsigargin binding pocket, and the pocket indicated by the blue spheres is the
cyclopiazonic acid (CPA), another mammalian SERCA inhibitor, binding pocket. However, two
of the pockets, indicated by the white and yellow spheres, have not been examined before, so
these were the pockets that we decided to explore further. Upon examination, it was discovered
that both of these new sites have an accessible cysteine residue present, and we found that to be
quite promising.

3.5

ION PREDICTION AND MODELING
Approximately one-third of all proteins bind at least one metal ion, and many different

metal ion binding proteins are found in humans. The structure of a protein determines its
function and interactions with other biomolecules. Metal ions function in stabilizing the protein,
inducing conformational changes upon binding, and may even participate in catalysis. Hence,
identifying metal ion binding sites is the key to understanding the functional mechanisms of
metal ion binding proteins.65

Metal ion binding proteins are identified and characterized experimentally by numerous
processes such as nuclear magnetic resonance spectroscopy, gel electrophoresis, metal affinity
column chromatography, electrophoretic mobility shift assay, absorbance spectroscopy, and
mass spectroscopy. These techniques require complex steps, special equipment, and are
unsuitable for unknown targets. Therefore, other means of detecting metal ion binding sites are
in high demand, and computational methods can offer some assistance to meet this demand.65

Generally, the part of the protein that interacts with substrates, ligands, or other proteins
are well conserved and are in close spatial proximity to each other although they may be far apart
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in the sequence. These residues usually make up approximately 10 to 30% of a protein sequence.
Cysteine, histidine, glutamate, and aspartate are the residues that most commonly bind metal ions
because the atoms in their polar or charged side chains are able to coordinate the ion.65

The fragment transformation method combines sequence and structural information
contained within spatially local fragments. Since the three-dimensional structure and residue type
are often conserved, similar binding regions can be found by comparing the types of residues and
their relative locations with those of computationally constructed metal ion binding residue
templates. First, structures of known metal ion binding proteins were obtained from the Protein
Data Bank. To be considered a metal ion binding protein, the protein must contain a polypeptide
chain. If more than one polypeptide chain is present, then only chains that contain residues
involved in metal ion binding were included. Also the length of the chain must be more than 50
residues. Next, these proteins were used to generate a template database. The residues that were
considered to be template residues must be at least partially within 3 Å of the metal ion center.
Also, a site needed to contain more than two metal ion binding residues in order to be considered
as a template.65

Once the template has been completely constructed, the fragment transformation method
aligns similar fragments that contain residues that are discontinuous in sequence but still
spatially close. Each residue is treated as an individual unit, and the unit used to align the query
protein and the templates is a triplet formed by the backbone N-Ca-C atoms of a given residue.65
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Figure 3.20: Schematic of the fragment transformation method for the prediction of metal ion
binding sites in proteins. (Figure duplicated with permission from Dr. Chih-Hao Lu at China
Medical University.)65
This method was able to outperform other methods and discovered that Ca2+
preferentially binds backbone oxygens of aspartate, glutamate, asparagine, and glycine; Cu2+
preferentially binds side chain oxygens and nitrogens of histidine; Mg2+ preferentially binds the
side chain oxygens of aspartate and glutamate; Fe3+ preferentially binds the side chain oxygens,
nitrogens, and sulfurs of histidine, glutamate, aspartate, cysteine, and tyrosine; Mn2+
preferentially binds side chain oxygens of aspartate, histidine, and glutamate; and Zn2+
preferentially binds side chain oxygens and nitrogens of cysteine and histidine. The method was
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also able to predict Ca2+ binding sites with 94.1% accuracy, Cu2+ binding sites with 94.9%
accuracy, Fe3+ binding sites with 94.9% accuracy, Mg2+ binding sites with 94.6% accuracy, Mn2+
binding sites with 95% accuracy, and Zn2+ binding sites with 94.8% accuracy. This averages to
94.6% accuracy overall.65
These are the results after our homology model of PfATP6 was submitted for metal ion
binding prediction via the fragment transformation method:

Table 3.1: Residues in PfATP6 that are able to bind Fe2+. The residues and their Fe2+ binding
scores are listed in the table. A residue with a score greater than 1.9 is predicted as being an Fe2+
binding residue.
Residue
Number
9
31
34
44
55
85
86
90
93
96
115
129
199
200
204
237
240
252
254
289
348
351
358

Fe Predicted
Score
3.12862
4.19643
4.19643
2.1846
3.79203
2.38
5.57443
5.57443
2.80675
2.80675
3.79203
2.1846
3.12862
3.12862
2.26405
4.80251
4.80251
2.26257
2.26257
1.99473
2.00946
2.00946
2.29645

Residue Type
HIS
GLU
ASP
GLU
GLU
LYS
HIS
GLU
ASP
GLU
GLU
GLN
GLU
ASP
ASN
GLU
HIS
ASP
GLN
ASP
THR
CYS
ASP
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Fe2+ Positive
3.12862
4.19643
4.19643
2.1846
3.79203
2.38
5.57443
5.57443
2.80675
2.80675
3.79203
2.1846
3.12862
3.12862
2.26405
4.80251
4.80251
2.26257
2.26257
1.99473
2.00946
2.00946
2.29645

380
383
386
388
389
392
395
429
479
514
518
520
687
696
697
702
714
715
729
734
739
747
751
769
781
782
846
847
849
852
873
877
881
891
997
1003
1025
1026
1034
1035
1038

ASP
THR
GLN
CYS
GLN
ASP
TYR
ASP
GLU
CYS
CYS
GLU
GLN
GLU
ARG
VAL
TYR
CYS
TYR
ASP
ASN
HIS
GLN
SER
TYR
TYR
ASP
GLU
ASP
THR
GLU
HIS
ASN
GLU
ASP
GLN
GLU
HIS
ARG
HIS
ASP

3.00557
2.61077
1.97509
2.61077
3.00557
4.989
4.989
5.18091
5.18091
3.46772
3.83556
3.14781
3.14781
3.01132
3.01132
3.46772
3.12309
3.83556
4.989
2.14142
4.989
3.49934
3.49934
3.12309
3.01132
3.12309
3.69845
3.69845
3.69845
2.2741
5.30663
5.30663
2.2741
2.29645
1.99473
3.82936
2.59582
3.15869
2.23251
4.04348
4.04348
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3.00557
2.61077
1.97509
2.61077
3.00557
4.989
4.989
5.18091
5.18091
3.46772
3.83556
3.14781
3.14781
3.01132
3.01132
3.46772
3.12309
3.83556
4.989
2.14142
4.989
3.49934
3.49934
3.12309
3.01132
3.12309
3.69845
3.69845
3.69845
2.2741
5.30663
5.30663
2.2741
2.29645
1.99473
3.82936
2.59582
3.15869
2.23251
4.04348
4.04348

1082
1083
1087
1090
1103
1108
1109
1144
1148
1168
1210
1211

PHE
TYR
HIS
GLN
TYR
ASP
HIS
ASN
GLU
HIS
PHE
TYR

3.89074
3.89074
3.65093
3.65093
3.65093
1.95727
1.95727
2.59582
3.15869
3.82936
5.42567
5.42567

3.89074
3.89074
3.65093
3.65093
3.65093
1.95727
1.95727
2.59582
3.15869
3.82936
5.42567
5.42567

We were not interested in every iron binding site in the protein, however. We were only
interested in the residues that are in the two unexplored pockets that AutoDock Vina found to be
artemisinin binding pockets and that were in close vicinity to the pocket’s cysteine residue.
Those residues are Lys85, His86, Glu1025, His1026, His1035, and Asn1144.

Figure 3.21: Fe2+ modeled into PfATP6 in the Cys-92 site using the fragment transformation
method. Fe2+ is shown as an orange sphere, Cys-92 and the Fe2+-binding residues, Lys-85 and
His-86, are also shown.
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Figure 3.22: Fe2+ modeled into PfATP6 in the Cys-1031 site using the fragment transformation
method. Fe2+ is shown as an orange sphere, Cys-1031 and the Fe2+-binding residues, Glu-1025,
Asn-1144 and Glu-1148, are also shown.

It can be clearly observed from Figures 3.21 and 3.22 that the modeled iron atom is very
far away (>10 Å) from the all-important cysteine residue in the pocket in both cases. In these
regions of the protein, the residues are located on loops which are highly flexible, so to get the
cysteine residues closer to the iron atom, we performed a loop refinement. We used the Prime
module of Schrödinger and selected the protein refinement option. We then chose the refine
loops option. The loop containing residues 83-95 for the Cys92 site and the loops containing
residues 1018-1042 and 1139-1154 were selected for the Cys1031 site. Ultra-extended serial
loop sampling was selected and constraints were chosen. For the Cys92 site: the sulfur atom of
Cys92 was constrained to 3 Å away from the iron atom with a force constant of 350 [all force
constants are given in units of kcal / (mol Å2)]; the delta nitrogen of His86 was constrained to 3

61

Å away from the iron atom with a force constant of 350; and the zeta nitrogen of Lys85 was
constrained to 3 Å away from the iron atom with a force constant of 200. Default options were
chosen for the rest. For the Cys1031 site: the sulfur atom of Cys1031 was constrained to 3 Å
from the iron atom with a force constant of 100; the epsilon oxygen of Glu1025 was constrained
to be 3 Å from the iron atom with a force constant of 100; the epsilon oxygen of Asn1144 was
constrained to be 3 Å from the iron atom with a force constant of 250; and the delta oxygen of
Glu1148 was constrained to be 3 Å from the iron atom with a force constant of 350. Default
options were chosen for the rest. This procedure resulted in a better position of the cysteine
residues.

Figure 3.23: Cys-92 site results after loop refinement.
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Figure 3.24: Cys-1031 site results after loop refinement.

3.6

PRE-TRANSITION STATE CALCULATION
Yikang Wu et. al. found that artemisinin is fully degraded by cysteine very rapidly in

vivo. However, artemisinin is fully consumed instantly in the presence of one equivalent each of
cysteine and FeSO4. This demonstrated the importance of the iron activation of cysteine.58 It was
important to find the optimum geometry, or pre-transition state, that should occur between the
Fe2+, artemisinin, and the cysteine residue in order for our proposed reaction to occur. Ab initio
quantum mechanics calculations were then utilized to determine the pre-transition state of our
complex for our reaction.
Ab initio is a Latin term that means “from the beginning”. In science, a calculation is ab
initio, or from first principles, if it is based on established and basic laws of nature without
making any assumptions.66 To find our pre-transition state, the Jaguar62 8.4 ab initio and
simulations module of the Schrödinger suite was utilized. The density functional theory hybrid
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functional B3LYP and the 6-31G basis set with polarized and diffuse functions that are
parameterized for transition metals (6-31G™*+) was used. Before the quantum mechanics
calculations could be commenced, however, we first needed a model system. To generate a
model, artemisinin was docked into the two sites using the Glide module of the Schrödinger suite
and a ferrous ion was placed nearby. During the docking procedure, artemisinin was allowed to
vary its conformation, but the protein was kept rigid. Since the protein naturally undergoes
certain conformational changes to accommodate the docked ligand, we altered the cysteine
residues in the sites so that the sulfurs would be closer to the O1 oxygen of artemisinin’s
peroxide bridge. Having the artemisinin accommodated in the geometry that we believe could be
the starting point of our reaction but having produced some extra steric clashes from rotamer
modifications, we performed side chain refinement of the rotamers using the default settings of
the Prime module of the Schrödinger suite. Subsequently, we performed a constrained
minimization of the whole complex while setting three constraints: the distance between the
oxygen of the water molecule and iron, the distance between O1 of artemisinin and the iron
atom, and the distance between the cysteine sulfurs and the iron atom were all set to 3±1 Å.
Having all the parameters for our model systems, we removed the protein and continued the
calculations on just the model system. Instead of using the entire cysteine residue, a methyl
group replaced the beta carbon on the cysteines and hydrogen atoms were added to have
methylthiol instead, and instead of simply a ferrous ion, we used ferrous chloride. The structure
was then minimized using the quantum mechanical method DFT B3LYP with the 6-31G™*+
basis set in vacuo. The geometry of the pre-transition state can be seen in Figure 3.25. The end
product of the proposed complex reaction was built by the modification of artemisinin and can
be viewed in Figure 3.26.
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Figure 3.25: Geometry of the pre-transition state calculated by Prime. Carbons are shown in
green, oxygens in red, hydrogens in white, sulfur in yellow, iron in light blue, and chlorines in
dark green. The distances between the atoms (in Å) are shown in magenta.

Figure 3.26: End product of the proposed complex reaction. Carbons are shown in green,
oxygens in red, hydrogens in white, sulfur in yellow, iron in light blue, and chlorines in dark
green. The distances between the atoms (in Å) can be seen in magenta, and the angles (in °) are
shown in green.
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3.7

GLIDE DOCKING AND INDUCED FIT DOCKING
Molecular docking is a method that is used to predict the preferred orientation of one

molecule relative to another when bound to each other in a stable complex. It is frequently used
to predict the binding orientation of small molecule drug candidates to their protein targets in
order to predict their binding affinity and activity.67

Figure 3.27: Schematic diagram illustrating the docking of a small molecule ligand (red) to
a protein receptor (black) to produce a complex.

We used both Glide standard precision docking, which assumes a rigid protein, and
Induced Fit Docking, which takes into account that many receptors alter their binding site to
conform to the shape and binding mode of the ligand. Both were used to determine which
program would produce the pre-transition state that was calculated previously. For the site
containing Cys-92, Induced Fit Docking was able to produce the desired pre-transition state
geometry better than Glide docking. The pre-transition state for the residues in the site
containing Cys-1031 was somewhat more difficult to retrieve. Glide docking and Induced Fit
Docking failed to give us an appropriate pose. We therefore used the best output that was
retrieved from Induced Fit Docking and used an appropriate, low energy rotamer of Cys-1031.
The requirements for our proposed active site were thus fulfilled. We then chose to perform a
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protein-ligand complex refinement using Prime. The Refine Protein-Ligand Complex option was
selected, and we chose to refine the atoms within 10 Å of the ligand using Monte Carlo
minimization. Then we constrained the distances between iron and O1 of artemisinin and
between C4 of artemisinin and the sulfur of Cys-1031 to be 2.5 Å, both with a force constant of
350. This procedure resulted in the retrieval of the pre-transition state that we sought.
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Figure 3.28: Different views of the docked pose of artemisinin in Cys-92 site. The coordinating
residues, Lys-85 and His-86, are shown a close distance from the iron atom which, in turn, is in
close proximity to the peroxide bridge of artemisinin. Cys-92 is also seen to be only a few Å
away from C4 of artemisinin, which is the optimal location to intercept the carbon radical.
68
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Figure 3.29: Different views of the docked pose of artemisinin in Cys-1031 site. The
coordinating residues, Glu-1025, Asn-1144, and Glu-1148, are shown a close distance from the
iron atom which, in turn, is in close proximity to the peroxide bridge of artemisinin. Cys-92 is
also seen to be only a few Å away from C4 of artemisinin, which is the optimal location to
intercept the carbon radical.

After receiving favorable results thus far, we enlisted the assistance of Dr. Sanjeev
Krishna to perform PfATP6 enzyme-specific assays. Our results were shared with him, and he
agreed to perform an experimental mutagenesis of residues in our two sites, and then assay
artemisinin against the mutants to determine if variations at these sites will alter the inhibitory
activity of artemisinin.

3.8

“MALARIA BOX”
In 2011, the Medicines for Malaria Venture (MMV) formed the Malaria Box project.

Extensive high-throughput screenings of millions of proprietary and publicly-available
compounds have led to the discovery of thousands of compounds with confirmed antimalarial
activity. Structures and descriptions of these compounds are publicly available. Researchers who
are part of the MMV analyzed over four million compounds that they acquired from companies
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such as GlaxoSmithKline and Novartis, and St. Jude Children’s Hospital. The program works by
mailing interested researchers a complete box-set of malaria tools, free of charge. The kit
contains over 400 antimalarial compounds in quantities large enough to run approximately 10
assays. The only stipulation to receiving the box is that receivers must promise to release any and
all research findings within two years.68, 69
Dr. Sanjeev Krishna, a collaborator at St. George’s University of London, has received
the malaria box compounds and assayed the compounds against PfATP6. Of the 400 compounds,
4 were found to be PfATP6 inhibitors. However, the binding site and mechanism of action for
these compounds are unknown. As a starting point, we decided to first find out where in PfATP6
the compounds bind. Using the same procedure that we used to find alternative artemisinin
binding sites, we proceeded to do blind docking studies for each of the compounds.

Figure 3.30: The structures and codes for the four malaria box compounds.
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Figure 3.31: AutoDock Vina results showing the pockets able to bind the four malaria box
compounds.

Using AutoDock Vina, we found approximately six pockets that are capable of binding
the malaria box compounds. Opportunely, two of the malaria box binding pockets are our two
unexplored artemisinin binding sites. The residues in these pockets were listed and sent to Dr.
Krishna. Mutagenesis studies will commence on these residues and the compounds will be
assayed again to find out if any of the mutations caused a decrease in the antimalarial activity of
any of the compounds.
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3.9

IN SILICO MUTAGENESIS
Mutagenesis is the term given to the procedure used to change the genetic information of

an organism. This can happen spontaneously in nature, from exposure to mutagens, or
experimentally.70 Site-directed mutagenesis is a technique that is used to make specific and
intentional changes to genes and it can be used to explore the biological activity of proteins.71 It
is a potent research tool used to study protein function, identify enzyme active sites, and design
novel proteins in drug discovery.72

There are numerous approaches to perform site-directed mutagenesis. While these
experimental methods are more reliable, they are more difficult than computational studies.
Computational studies can add efficiency and speed to experimental methods by pre-filtering
with in silico predictions of non-synonymous single nucleotide polymorphisms (nsSNP).
Although it may never be accurate enough to completely replace wet-lab experiments,
computational methods may help in selecting and prioritizing a small number of likely
candidates from available data. Studies have shown a range of computational approaches that are
capable of producing estimates of the functional effects of polymorphisms.73

In order to truly know if our two new sites are actual artemisinin binding sites, certain
residues in the pockets will need to be mutated. The mutant protein will then be treated with
artemisinin to determine if the mutations had any effect on the activity of artemisinin. To aid in
our experimental mutagenesis, a program named SNAP (screening for non-acceptable
polymorphisms) was utilized to find if the mutation of certain residues in our protein would
affect its function. SNAP is a neural network-based method for the prediction of the functional
effects of nsSNPs. Sequence information is the only needed input. In a cross-validation test on
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over 80,000 mutants, SNAP was able to identify 80% of the non-neutral (functionally-distinct)
substitutions with 77% accuracy and 76% of the neutral substitutions with 80% accuracy. This
was a marked improvement over existing methods. More importantly, SNAP introduced a wellcalibrated measure for the reliability of each prediction.73

Experimental mutagenesis studies have previously been performed on PfATP6. This
study demonstrated that if Leu263 is mutated to E263, the protein’s function changes and
artemisinin’s activity on the protein decreases.44 We wanted to find out if SNAP would classify
this mutation as non-neutral. The sequence for PfATP6 was uploaded into the SNAP software
and the L263E mutation was selected. The software was able to accurately classify this mutation
as non-neutral with 58% predicted accuracy as shown in Figure 3.32. Another documented
mutation, S769N, was reported as having no effect on PfATP674, so this mutation was selected in
the SNAP software. SNAP found this mutation to be neutral with 92% predicted accuracy as
seen in Figure 3.33. Based on these results, SNAP software may be a reliable source for
predicting the effect of mutations in our protein.
#Query sequence: snapfasta
Including only predictions with:
RI >= 0
Expected Accuracy >= 50%
nsSNP Prediction Reliability Index Expected Accuracy
---------------------------------------------------L263E Non-neutral
0
58%

Figure 3.32. SNAP prediction for the L263E mutation.

nsSNP
----S769N

#Query sequence: snapfasta
Including only predictions with:
RI >= 0
Expected Accuracy >= 50%
Prediction Reliability Index Expected Accuracy
-----------------------------------------------Neutral
6
92%

Figure 3.33: SNAP prediction for the S769N mutation.
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As a starting point, we decided to use the cysteine residues in the pockets. We chose to
mutate them to similar residues and see if the SNAP program would classify the mutation as
being neutral or non-neutral. The mutations we chose were Cys-Asp, Cys-Asn, Cys-Ala, CysVal, and Cys-Ser.

Table 3.2: SNAP predictions for numerous mutations in PfATP6.
Original Residue

Mutated Residue

Result

Cys92

Asp92

Non-neutral

Cys92

Asn92

Non-neutral

Cys92

Ala92

Non-neutral

Cys92

Val92

Non-neutral

Cys92

Ser92

Non-neutral

Cys1031

Asp1031

Neutral

Cys1031

Asn1031

Neutral

Cys1031

Ala1031

Neutral

Cys1031

Val1031

Neutral

Cys1031

Ser1031

Neutral

From Table 3.2, it is predicted that any of these mutations occurring at Cys92 will cause
a non-neutral change. This means that mutating Cys92 will change either the shape or the
function of PfATP6. It is also worth noting that any of these mutations occurring at the Cys1031
position was predicted to be a neutral mutation meaning it will not cause a change in the shape or
function of the protein. These results were given to our collaborator who will perform the
experimental mutagenesis. The results of the experimental mutagenesis will not only prove or
disprove our hypothesis, but it will either offer more evidence for the accuracy of SNAP or
condemn its practicality.
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To determine if our docking algorithm could also detect how the mutation of certain
residues could alter the docking poses and scores and to test for any correlation between them,
we mutated Cys92 and Cys1031 to the residues that we submitted to the SNAP program. The
mutant proteins were then prepared and minimized, and receptor grids were generated for each.
Artemisinin was then docked into each receptor to retrieve the best docking score for each
mutant-artemisinin complex. Table 3.3 shows the differences in the docking scores of
artemisinin against the mutant proteins in comparison to the native protein.

Table 3.3: Docking scores of artemisinin against mutant PfATP6 proteins.
Residue

Docking score

Cys92

-4.045

Asp92

-4.016

Asn92

-3.215

Ala92

-3.811

Val92

-3.580

Ser92

-3.670

Cys1031

-4.380

Asp1031

-4.780

Asn1031

-4.740

Ala1031

-4.802

Val1031

-4.575

Ser1031

-4.786

According to the docking scores, all of the mutations at the Cys92 residue resulted in
artemisinin binding poses with worse docking scores (more positive) as compared to the native
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protein, and all of the mutations at the Cys1031 residue resulted in artemisinin binding poses
with better docking scores (more negative) as compared to the native protein. So the SNAP
program and the manual in silico mutagenesis/docking of artemisinin show an opposite trend in
the two sites. Only the experimental mutagenesis will show which one was more accurate.

77

CHAPTER 4. STRUCTURE-BASED VIRTUAL SCREENING

*Shuneize E. Slater, Khaled M. Elokely, Kuldeep K. Roy, Manal A. Nael, Robert J.
Doerksen, Mitchell A. Avery, Unpublished.
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4.1

INTRODUCTION
High throughput screening (HTS) involves the biological testing of large numbers of

small molecules for a specific pharmaceutical effect. It is a major route toward discovering novel
compounds. Advances in computational methods have allowed virtual screening to speed up
modern drug discovery programs. Virtual screening, or in silico screening, is the selection of
compounds by evaluating their desirability in a computational model. Since its debut over a
decade ago, there has been a clear upward trend in publications on this particular subject area.
The progress that has been made in this field has fostered its high acceptance in use, and it can be
easily integrated in the drug discovery and development process. Virtual screening can be
divided into two main categories: similarity- or ligand-based virtual screening (LBVS) and
target- or structure-based virtual screening (SBVS).75

Ligand-based virtual screening relies on the assumption that structurally similar
molecules will exhibit similar binding properties towards a target protein. It generally provides
significant enrichment over the random selection of compounds and has been successfully
applied for the identification of bioactive lead compounds for a wide range of drug targets. There
is a diverse set of LBVS techniques such as small molecule alignment, 1D, 2D, and 3D
descriptor-based screening, shape-based searching, pharmacophore-based searching, recursive
partitioning, and graph-based similarity assessment.76

Structure-based virtual screening is used if structural information is available for a target.
Quick SBVS algorithms are used to place the molecules inside the active site or a specified
pocket of the biological target (docking), after which they are then ranked according to their
calculated binding affinity estimations (scoring). There are currently a vast number of different
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docking and scoring methodologies employed in the pharmaceutical industry. Most docking
algorithms can be classified into four methods: force field-based, evolutionary, fragment-based
incremental, and shape complementary-based methods. These provide approximations of the
expected conformation and orientation of the ligands in the binding site. Protein flexibility and
the importance of water molecules have also been incorporated into most docking schemes.
Although a large amount of research has been undertaken in the generation of better docking
algorithms and scoring functions, the discrimination of true binders from the decoys remains a
challenge.77

4.2

PROCEDURE
To determine whether targeting our two new pockets will result in the discovery of novel

PfATP6 inhibitors, we performed virtual screening into the pockets. All purchasable compounds
were downloaded from the ZINC database. This was approximately 20 million compounds.
Filter 2.1.1, a drug filter, was used to eliminate the compounds that do not follow Lipinski’s rule
of five and structures with metabolically vulnerable groups. This resulted in approximately 11
million compounds remaining. We then used OMEGA 2.4, a program from OpenEye Scientific
that is able rapidly and effectively to generate conformers of large databases, to generate a
maximum of 300 conformers per ligand within an energy window of 10 kcal/mol. These
conformers were docked into the two sites using OpenEye Scientific software. The one thousand
best scoring compounds were selected. Canvas from Schrödinger, which uses fingerprinting and
substructure matching to screen millions of compounds in seconds, was used to select
approximately fifty of the most diverse compounds from the set.
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ZINC00506860

ZINC00192016

ZINC04337585

ZINC80290460

ZINC80212637

ZINC77506749

ZINC76658501

ZINC72623135
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ZINC72435140

ZINC67867915

ZINC67786201

ZINC67688838

ZINC65375585

ZINC64025512

ZINC63846532

ZINC63388047
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ZINC58218624

ZINC51331099

ZINC02659645

ZINC03002706

ZINC04127198

ZINC05604299

ZINC08683581
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ZINC08780032

ZINC08928022

ZINC13831596

ZINC15018344

ZINC16981849

ZINC19331111

ZINC25500407

ZINC31169813

ZINC39001420
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ZINC42384326

ZINC72388585

ZINC67757786

ZINC57160091

ZINC59349840

ZINC46947075

ZINC39605861
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ZINC39446033

ZINC04742288

ZINC08133013

ZINC09124247

ZINC15733800

ZINC19821533

ZINC20391478

Figure 4.1: The 46 most diverse compounds from the virtual screening. The 18 remaining after
visual inspection and determination of commercial availability are shown in red.

The 46 diverse compounds were then visually inspected for ionization issues and
problematic functional groups. Other than the docking scores and poses, selection was also based
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on a combination of the number of good interactions, the general match of hydrophobic or
hydrophilic space, logP, and the potential for metabolism. This resulted in twenty-five
compounds remaining. Of these 25, seven were not commercially available at the time. A quote
was requested and a price list was obtained from Ambinter. These eighteen compounds, or a
subset thereof, will be purchased and tested for both their antimalarial activity and their PfATP6
inhibitory activity.

Table 4.1: The clogP values and docking scores for the eighteen compounds chosen for
antimalarial assay and PfATP6 inhibition.
COMPOUND

clogP

DOCKING SCORE

ZINC00506860

0.935

-11.922

ZINC00192016

-2.1446

-11.462

ZINC67867915

2.7312

-11.547

ZINC67786201

2.4537

-11.971

ZINC58218624

1.4802

-12.099

ZINC02659645

2.482

-11.408

ZINC03002706

-0.297

-11.534

ZINC04127198

-1.8566

-12.008

ZINC08780032

1.726

-11.495

ZINC13831596

-2.4224

-11.563

ZINC15018344

1.3826

-11.582

ZINC16981849

1.247

-11.401

ZINC19331111

1.4276

-11.405

ZINC31169813

-0.8467

-11.500

ZINC67757786

3.0399

-12.789

ZINC57160091

-2.670

-13.757

ZINC09124247

3.1904

-11.71

ZINC15733800

2.2095

-11.404
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Figure 4.2: Docking poses of the 2 best-scoring virtual screening hits in each site, shown with
green carbons, and the residues that interact with them, shown with gray carbons. Top left,
ZINC57160091; top right, ZINC67786201; middle, ZINC67757786; bottom, ZINC04127198.
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CHAPTER 5. DEVELOPING A STRUCTURE-ACTIVITY RELATIONSHIP FOR THE
TWO NEW ARTEMISININ BINDING SITES

*Shuneize E. Slater, Mohamed Jihan, Robert J. Doerksen, Mitchell A. Avery, Unpublished.
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5.1

INTRODUCTION
Structure-activity relationship, or SAR, is the study of the correlation between the

structure of a drug and its biological activity. SARs are essential for the design of therapeutics
with the highest potency but the least adverse effects.78 Developing a SAR helps in determining
the chemical groups at a specified position in the drug structure that are responsible for
producing a biological effect in the target organism. Medicinal chemists use SARs to modify
drug structures and test the modifications for their biological activities.79

5.2

PROCEDURE
Currently in our research group, sixteen derivatives of artemisinin were designed. These

were used to develop a SAR against the two new sites that we discovered in PfATP6. To begin,
the sixteen compounds were drawn in ChemDraw and saved as individual .sdf files. The files
were then uploaded to the Maestro interface of the Schrödinger suite and minimized to obtain
their 3-D conformations. The 3-D structures were then prepared using the LigPrep module of
Schrödinger which prepares the ligands by converting them based on their tautomeric and
protonation states at certain pH ranges. Next the compounds were docked into both sites using
both Glide docking and Induced Fit Docking to retrieve their docking scores and poses.

1

2

3
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4

5

7

6

8

9
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11

12

13

14

15

16

Figure 5.1: Structures of the 16 artemisinin derivatives used in this study.
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Table 5.1: Docking scores of artemisinin derivatives in Cys92 site.
Compound

Docking Score

1

-4.567

2

-3.837

3

-4.593

4

-4.370

5

-3.088

6

-3.626

7

-4.379

8

-3.534

9

-4.130

10

-4.273

11

-4.050

12

-3.466

13

-3.381

14

-3.568

15

-3.633

16

-3.753

artemisinin

-4.045

Table 5.1 shows the docking scores of artemisinin and the sixteen artemisinin derivatives
used in this study against the site containing Cys92. Seven of these derivatives, 1, 3, 4, 7, 9, 10,
and 11 are predicted to be better binders to PfATP6 at this site than artemisinin itself.
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Table 5.2: Docking scores of artemisinin derivatives in Cys1031 site.
Compound

Docking Score

1

-6.456

2

-6.197

3

-5.140

4

-4.666

5

-4.805

6

-5.237

7

-4.541

8

-4.689

9

-4.393

10

-5.331

11

-5.211

12

-4.801

13

-4.743

14

-3.061

15

-4.543

16

-4.298

artemisinin

-4.380

Table 5.2 shows the docking scores of artemisinin and the sixteen artemisinin derivatives
used in this study against the site containing Cys1031. Amazingly, all of the derivatives scored
better than artemisinin in this site except for compounds 14 and 16. All sixteen of these
compounds are currently being synthesized and will be assayed for their antimalarial activities
and PfATP6 inhibitory activities. Once the assays are completed, we will be able to determine if
there is indeed a correlation between the structures and their biological activities.
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Figure 5.2: The top ranked compounds in the site containing Cys92. Top left, 1; top right, 3;
middle left, 4; middle right, 7; bottom left, 9; bottom right, 10.
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Figure 5.2: The top ranked compounds in the site containing Cys92. Top left, 1; top right, 2;
middle left, 3; middle right, 6; bottom left, 10; bottom right, 11.
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CHAPTER 6. PfATP6 AND PfTCTP

*Shuneize E. Slater, Chinni Yalamanchili, Amar Chittiboyina, Mitchell A. Avery,
Unpublished.
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6.1

INTRODUCTION
It is well known that artemisinin derivatives are very potent antimalarials. Specific

malaria proteins become labeled when intact Plasmodium falciparum-infected blood cells are
exposed to radiolabeled artemisinin. One of the proteins, a translationally controlled tumor
protein (TCTP), was eluted from 2-dimensional gels, partially sequenced, then cloned and
expressed in E. coli.80 TCTP was first described in the 1980s and was preciously named fortilin,
Q23, p23, and p21.81
PfATP6 is found in the membrane of the parasite’s food vacuole. Here, there is an
abundance of heme and iron from digested hemoglobin. To determine if PfTCTP is located in the
food vacuoles as well, isolated food vacuoles and hemozoin were examined by
immunofluorescence. The results suggest that PfTCTP is either located in the food vacuole
stroma or the membrane. To find its exact location, immunoelectron microscopy with
immunogold labeling was used. Gold particles were found in the cytoplasm, the food vacuolar
membrane and in other parasite-derived membranes. It is also known that PfATP6 is able to bind
calcium ions. To discover if PfTCTP is also able to bind calcium ions, a 45Ca overlay assay was
used. Calcium binding proteins tend to migrate more rapidly in SDS gels in the presence of
calcium. The results of the assay indicated that PfTCTP does in fact bind calcium ions.81

All of the previous information suggested that PfTCTP is a target molecule for
artemisinin; however, the site of interaction had not been elucidated. It was believed that the
single cysteine residue of the protein was responsible for drug binding. However, once the
crystal structure of PfTCTP was determined, the structure revealed that the cysteine residue is
buried deep inside the protein and is inaccessible. So, in silico blind docking was performed to
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find potential binding sites in the protein. Out of thirteen sites found, two were selected for
further analysis based on their correlation with experimental evidence.81

6.2

PROCEDURE
After finding this information, we decided to compare the two potential artemisinin

binding sites in PfTCTP to our two potential artemisinin binding sites in PfATP6. The idea is
that if artemisinin is able to bind to both proteins, then there should be some similarities between
the binding sites. Since crystals of the artemisinin-PfTCTP complex could not be obtained, we
downloaded the crystal structure of PfTCTP (PDB ID: 3P3K) from the Protein DataBank and
prepared and minimized it using the Protein Preparation Wizard of the Schrödinger suite. Glide
was then used to generate receptor grids for the two sites by specifying the binding site residues.
For position 1, the binding site residues were Ile95, Met99, Glu100, Ala103, Phe117, Lys118,
Ala121, Gln122, and Ile125. For position 2, the specified residues were Phe28, Glu29, His127,
Asn131, Asp134, Phe135, Ser152, Tyr153, Tyr154, and Gly156. After the receptor grids were
generated, we docked artemisinin into the two sites in order to attempt to reproduce the exact
binding poses that were reported. Once the best matching poses were retrieved, we superimposed
the two complexes of PfTCTP with our two complexes of PfATP6 by aligning the artemisinin
structures in the sites. By doing so, this allowed us to compare the residues in both proteins that
are interacting with certain features in artemisinin and to study whether these residues share any
similarities.
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Figure 6.1: Structure of PfTCTP. The location of artemisinin binding position 1 is shown in blue
and of artemisinin binding position 2 is shown in red.

Figure 6.2: Artemisinin docked into position 1 of PfTCTP.
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Figure 6.3: Artemisinin docked into position 2 of PfTCTP.

Once the superimposition of the sites is complete and the similarities between the sites
have been documented, we will take approximately 50 compounds that were synthesized and
assayed in house and dock them into both sites of the proteins to determine whether in silico
studies can aid in explaining the activity trend of the compounds.
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CHAPTER 7. CONCLUSIONS AND FUTURE PLANS
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In conclusion, malaria has been a major problem in our world for centuries. It is
an extremely fatal, yet preventable and treatable disease. Over the years, numerous efforts have
been made in the discovery of both natural and synthetic therapeutics to treat malaria. Quinoline
derivatives such as quinine and chloroquine have offered relief for years, but resistance towards
these drugs has emerged. To thwart malaria, many ventures went underway to find novel
therapeutics. One such venture isolated the compound artemisinin from Artemisia annua. This
compound was found to be a very potent antimalarial. Although artemisinin has been used for
decades to treat malaria, exactly how is exerts its antimalarial effects is still a mystery. Many
research groups have offered hypotheses as to its exact mechanism of action, but no consensus
has been reached. One group offered the protein Plasmodium falciparum ATPase 6 as the
possible target for artemisinin. They predicted that artemisinin acts in the same manner as the
compound thapsigargin towards the mammalian ATPase. However, we found a few concerns
with that mechanism of action and ventured out to find a more plausible mechanism of action for
artemisinin against PfATP6. Many computational methods, such as pocket searching, blind
docking, ion prediction and modeling, and in silico mutagenesis, have been exhausted in the
search to verify our hypothesis. Our results are proving to be quite favorable. We also searched
for PfATP6 binding sites for four “malaria box” compounds that were first found to possess
antimalarial activity and then PfATP6 inhibitory activity. To verify both our hypothesis of the
two new PfATP6 binding sites for artemisinin and the four “malaria box” compounds, an
experimental mutagenesis study will be performed by collaboration with Krishna and colleagues
at St. George’s University of London. This will determine whether our two sites truly are
artemisinin binding sites and will verify the “malaria box” binding sites as well.
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To further determine if targeting our new sites could result in the discovery of novel
antimalarials, virtual screening was executed utilizing docking into the pockets. A library of
approximately 20 million compounds was downloaded and after a few steps, nineteen remained.
These compounds will be purchased, and both an antimalarial assay and a PfATP6 enzymebased assay will be performed on these compounds to determine their activities.

In the very near future, the synthesis of the artemisinin derivatives will be completed and
they will be tested for both their antimalarial activity and their PfATP6 inhibitory activity. This
will aid in the development of a structure-activity relationship for PfATP6 inhibitors. The work
on PfTCTP will also be completed.

Finally, with the occurrence of so many reasonable mechanisms of action, many
of them being difficult to refute, we think it is likely that artemisinin and its derivative peroxides
act by a combination of various mechanisms. If true, it will be extremely difficult to construct a
predictive single pharmacophore model for this class of drugs. Future researchers will face these
difficulties. As a final note, how do we explain the activities of so many diverse peroxides
against P. falciparum? How do we reconcile bioactive 13-Carbaartemisinin with these
mechanisms, and finally, how do we explain the potent antimalarial activity of 4,5secoartemisinin 1 (Scheme 7.1)82, prepared by total synthesis by the Avery research group many
years ago? For example, as shown in Scheme 7.1, formation of a C-4 radical seems impossible
upon exposure to Fe(II). Instead, we see the loss of acetone from 2 to give 3, a carboxyl radical,
which is known to lose CO2 to form a carbon radical such as 4. One can conceive of 4
undergoing ring opening to form an enolate radical 5, which is more stable than the carbon
radical 4. Which, if any, of these intermediates can be reconciled with the MOA forwarded in
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this proposal for PfATP6? Is the Haynes MOA more compatible with this ring-scissioned
version of artemisinin? Also, can 4 or 5 achieve an orientation within the proposed sites
containing C1031 or C92 to bind with their cysteine thiols? These are the sorts of questions that
are to be struggled with in the future and support a multi-mechanistic view of the MOA for
artemisinin.

Scheme 7.1: Fe(II)-mediated ring opening.
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